Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736207 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL18531996 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL2736271 | 0.90 | CYP3A4 (0.54) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL13535190 | 0.89 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL10201898 | 0.88 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL10200504 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL2736139 | 0.88 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL14638407 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL13535195 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL3361380 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| EP-3112355-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2487165-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2487163-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487162-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487161-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2487166-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-07-27 | — | — | EP | disclosed |
| EP-2487162-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487166-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148374-B2 | Concurrent administering of drugs; side effect reduction | GILEAD SCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8067449-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7939553-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108617-A1 | co-administered drug (as HIV protease inhibiting compound, an HIV (non)nucleoside/nucleotide inhibitor of reverse transcriptase, capsid polymerization inhibitor, interferon, ribavirin analog) by inhibiting cytochrome P450 monooxygenase; ureido- or amido-amine derivatives; side effect reduction | PNP, UNG, PNPO | CYP3A4 11/4885CYP2D6 50/4885CYP2C19 119/4885 |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 149/4885CYP2D6 92/4885CYP2C19 476/4885 |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C19 716/4885 |
| US-20100189687-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 160/4885CYP2D6 105/4885CYP2C19 576/4885 |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 160/4885CYP2D6 105/4885CYP2C19 576/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C19 716/4885 |
| US-20090291952-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C19 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.